Introduction {#sec1-1}
============

Myelodysplastic syndromes (MDS) are a heterogeneous group of clonal hematopoietic stem cell disorders and they are characterized by ineffective hematopoiesis, morphologic abnormalities in one or more cell lines in an usually cellular bone marrow and a predilection to the development of acute myeloid leukemia (AML) \[**[@R1],[@R2]**\]. A succession of MDS classification systems has been developed to facilitate the prediction of the risk of progression to AML and overall survival \[**[@R2]-[@R5]**\].

For a rapid evaluation of the outcome in myelodysplastic patients, non-cytogenetic prognostic scores can be used. The following prognostic scores are not based on a cytogenetic analysis and they are reliable to evaluate recently diagnosed patients with myelodysplastic syndrome: Spanish score \[**[@R6]**\], Goasguen score \[**[@R7]**\], Dusseldorf score \[**[@R8]**\] and Bournemouth score \[**[@R9],[@R10]**\].

Aim: Our aim was to demonstrate that we can still relay on non-cytogenetic prognostic scores to evaluate patients who were diagnosed with myelodysplastic syndrome, and that age and gender are important factors in the outcome of these patients.

Matherials and method: This study was conducted in the Department of Hematology of the Emergency University Hospital Bucharest during October 2008 and October 2012. 110 patients were enrolled; only patients at diagnose were evaluated. The following tests were performed for each patient: cells blood count, bone marrow smear (to evaluate the percent of myeloblasts) and level of lactate dehydrogenase (LDH).

Results: The Spanish score is calculated based on the following parameters: percent of bone marrow blasts, platelets number and patient age. Male sex and age higher than 60 years are associated with high-risk in the studied cases (**Table [1](#T1){ref-type="table"},[2](#T2){ref-type="table"}**).

###### 

Distribution of patients based on Spanish score and age

                                      Patient age                                   Total
  --------------- ------------------- ----------------------- --------------------- -------
                                      Younger than 60 years   Older than 60 years   
                  Low risk            15                      42                    57
  Spanish score   Intermediate risk   5                       35                    40
                  High risk           1                       12                    13
  Total                               21                      89                    110

###### 

Distribution of patients based on Spanish score and gender

                                      Patient sex          Total
  --------------- ------------------- ------------- ------ -------
                                      female        male   
                  Low risk            32            25     57
  Spanish score   Intermediate risk   19            21     40
                  High risk           4             9      13
  Total                               55            55     110

Another prognostic score which does not use the cytogenetic analysis is Goasguen score and it is based on: hemoglobin level, platelets number and percent of bone marrow blasts. According to this score: male sex and age, patients older than 60 years, present characteristics associated with an intermediate risk (**Table [3](#T3){ref-type="table"},[4](#T4){ref-type="table"}**).

###### 

Distribution of patients based on Goasguen score and gender

                                       Patient sex          Total
  ---------------- ------------------- ------------- ------ -------
                                       female        male   
                   Low risk            30            23     53
  Goasguen score   Intermediate risk   25            32     57
  Total                                55            55     110

###### 

Distribution of patients based on Goasguen score and age

                                       Patient age                                   Total
  ---------------- ------------------- ----------------------- --------------------- -------
                                       Younger than 60 years   Older than 60 years   
                   Low risk            12                      41                    53
  Goasguen score   Intermediate risk   9                       48                    57
  Total                                21                      89                    110

Dusseldorf prognostic score is calculated based on the percent of marrow blasts, LDH, hemoglobin level and platelets number. 43.5% of the evaluated patients were classified with intermediate risk and 34.5% with high risk. Age over 60 years and female gender were associated with pronounced risk in the examined group (**Table [5](#T5){ref-type="table"},[6](#T6){ref-type="table"}**)..

###### 

Distribution of patients based on Dusseldorf score and age

                                         Patient age                                   Total
  ------------------ ------------------- ----------------------- --------------------- -------
                                         Younger than 60 years   Older than 60 years   
                     Low risk            4                       7                     11
  Dusseldorf score   Intermediate risk   11                      50                    61
                     High risk           6                       32                    38
  Total                                  21                      89                    110

###### 

Distribution of patients based on Dusseldorf score and gender

                                         Patient sex          Total
  ------------------ ------------------- ------------- ------ -------
                                         female        male   
                     Low risk            5             6      11
  Dusseldorf score   Intermediate risk   33            28     61
                     High risk           17            21     38
  Total                                  55            55     110

Bournemouth score takes into account the percent of bone marrow blasts, neutrophils, platelets number and hemoglobin level. By examining this score we found that age \> 60 years correlated with a higher frequency of risk, but no significant differences regarding the sex of patients were observed in our group (**Fig. [1](#F1){ref-type="fig"},[2](#F2){ref-type="fig"}**).

![Graphic representation of Bournemouth score and age](JMedLife-07-335-g001){#F1}

![Graphic representation of Bournemouth score and gender](JMedLife-07-335-g002){#F2}

From the 110 patients enrolled in this study, only 25 evolved to acute myeloid leukemia. This group consisted of 9 women and 16 men; at the time of diagnosis of acute leukemia, five of them were aged under 60 years and twenty over 60 years (**[Table 7](#T7){ref-type="table"}**).

###### 

Distribution of patients who evolved from myelodysplastic syndrome to acute myeloid leukemia

  Patients age            Number of patients   Patients sex   Number of patients   Percent
  ----------------------- -------------------- -------------- -------------------- ---------
  Younger than 60 years   5                    Female         9                    36,0
  Older than 60 years     20                   Male           16                   64,0
  Total                   25                   Total          25                   100,0

40% of the female and 75% of the male patients who evolved to acute 7 leukemia have the most severe prognostic risk demonstrated by applying all 4 scores above.

In the group of patients older than 60 years: 80.76% of them transformed from a myelodysplastic entity into AML, and 23/25 died. In the other group, with patients younger than 60 years, 25% of the patients evolved to AML and 3/5 died by the end of the study.

Discussions {#sec1-2}
===========

Over the past 25 years, diagnostic criteria have been set up to diagnose the MDS: 2 classification systems (French-American-British \[FAB\] and World Health Organization \[WHO\]) and several prognostic-scoring systems, the most common being the International Prognostic Scoring System (IPSS), have been widely used \[**[@R11]**\].

Regarding the clinical outcomes, other studies have suggested the importance of a variety of clinical features, including different numbers or types of cytopenias (less than 1 or 2 cytopenias, thrombocytopenia, anemia versus neutropenia) \[**[@R12]**\], bone marrow blast percentages \[**[@R13],[@R15]**\], and cytogenetic abnormalities \[**[@R4],[@R16]**\]. Because the vast majority of primary MDS patients are elderly, age-stratified morbidity and mortality figures are needed regarding their clinical outcome \[**[@R4]**\]. Our data are similar to those previously reported, showing that age \> 60 years is an important factor associated with poor prognosis and survival.

Both myelodysplasia and myeloproliferative diseases are uncommon in childhood, perhaps because small series of patients are the norm \[**[@R1]**\]. When all the patients were included in the analysis, sex, age, the proportion of blasts in blood or bone marrow, or the presence of abnormal localization of immature precursors (ALIP) in the bone marrow trephine were not of prognostic significance \[**[@R1]**\]. Our study revealed that male sex is more frequently associated with severe prognostic risk compared to female gender.

Cytogenetic findings have an established role in the diagnosis and assessment of prognosis of MDS and are emerging as an important factor in the treatment selection and monitoring response to therapy \[**[@R2]**\]. Unfortunately, the IPSS system underweights the clinical importance of severe (life-threatening) neutropenia and thrombocytopenia, in determining the need for therapeutic intervention. Although imperfect in its clinical utility, the IPSS has been very useful in examining and comparing the outcomes of clinical trials \[**[@R11]**\]. Since its publication, its utility has been confirmed in many institutions and refinements of the IPSS (e.g. the WHO classification-based prognostic scoring system, WPSS) continue to be proposed \[**[@R11],[@R17]**\].

In addition, cytogenetic subgroups and prognostic variables have recently been suggested as providing improved prognostic evaluation of clinical outcomes of primary MDS patients \[**[@R18],[@R20]**\]. Although the established prognostic scoring systems are based on conventional cytogenetics, some studies showed that chromosomal abnormalities detected by fluorescence in situ hybridization (FISH) may provide prognostic information \[**[@R21],[@R22]**\], and may be useful in supporting the clinical decision making in the selected cases, such as those with del(5q) or with del(7q) or monosomy 7 \[**[@R23]**\].

Conclusions {#sec1-3}
===========

The diagnosis of myelodysplastic syndromes is a multi-step procedure and the evaluation of the outcome of these patients can sometimes be difficult to assess. Using simple laboratory tests, such as cells blood count, bone marrow smears and level of lactate dehydrogenase, 4 non-cytogenetic prognostic scores can be applied to obtain important information about the risk assessment of the patients. By the end of this study, we concluded that age \> 60 years and male gender are important predisposing factors in survival.
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